Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Huynh Cao, Kenneth Yamamoto, Li-Xi Yang, Robert Weber
Index: Anticancer Res. 33(9) , 3879-85, (2013)
Full Text: HTML
Abstract
Hodgkin lymphoma (HL) is characterized by malignant Reed-Sternberg cells which express CD30. Current National Comprehensive Cancer Network guidelines for patients with advanced HL (stage III/IV disease) recommend adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), or escalated bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as first-line regimens. ABVD appears to be as effective, with fewer side effects, as escalated BEACOPP. Escalated BEACOPP leads to a greater progression-free survival but no difference in overall survival. Recent advancements in technology have enabled an exciting shift to molecular-targeted cancer therapy. Brentuximab vedotin, a CD30-directed antibody conjugate, specifically targets malignant HL cells. It is approved by the Food and Drug Administration for the treatment of systemic anaplastic large-cell lymphoma and refractory HL that has progressed after autologous stem cell transplant, or after two prior multiagent chemotherapy regimens among patients ineligible to receive a transplant.
Related Compounds
Related Articles:
2014-12-01
[Eur. J. Cancer 50(18) , 3243-61, (2014)]
2015-02-01
[Mol. Cell Biochem. 400(1-2) , 41-50, (2015)]
2014-12-01
[Biochim. Biophys. Acta 1841(12) , 1672-82, (2015)]
2015-02-01
[Fundam. Clin. Pharmacol. 29(1) , 62-71, (2015)]
2014-12-01
[Eur. J. Nutr. 53(8) , 1645-57, (2014)]